Background & Aims-Iron deficiency is often observed in obese individuals. The iron regulatory hormone hepcidin is regulated by iron and cytokines IL6 and IL1β. We examine the relationship between obesity, circulating levels of hepcidin and IL6 and IL1β, and other risk factors in patients with non-alcoholic fatty liver disease (NAFLD) with iron deficiency.
Introduction
Obesity and iron deficiency are considered the two most common nutritional disorders worldwide (1) . The association between obesity and iron status was first described by Wenzel in 1962, who noted that obese adolescents had lower serum iron compared to nonobese adolescents (2) . A diet rich in carbohydrates and fats and poor in nutrients such as iron, combined with a greater iron requirement in obese individuals may play a role (3). However, Menzie et al evaluated the role of dietary factors in obese ID individuals and did not find an association between iron intake and ID (4) . More recently, research has focused on the role of systemic, obesity-related, low-grade inflammation leading to ID via increased hepcidin expression. (5) (6) (7) .
In response to increased iron stores, hepcidin, the iron regulatory hormone, binds and internalizes the cellular iron export protein ferroportin, thus downregulating iron efflux from the enterocyte, macrophage and hepatocyte (8) . Conversely, decreased/deficient iron stores down regulate hepcidin in order to restore iron balance to appropriate physiologic levels. Hepcidin expression is also increased in chronic inflammation, by inflammatory cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) via STAT3 (9) . Hepcidin is predominantly expressed in the liver, but also in subcutaneous and visceral adipose tissue, albeit at such a low level it may not contribute to systemic hepcidin levels (6, 10) . Thus, the impact of obesity-induced hepcidin upregulation and the relationship between liver vs adipose-derived hepcidin, and iron regulation in the setting of obesity is not well understood.
NAFLD is the most common liver disease in the US with an estimated prevalence of 30% among US adults and is associated with obesity, type 2 diabetes mellitus, and the metabolic syndrome (11) . Up to a third of all patients with NAFLD progress to the more severe form called non-alcoholic steatohepatitis (NASH), characterized by hepatocellular ballooning, inflammation and variable fibrosis (12) . We have previously shown, using a cutoff of serum ferritin (SF) 1.5 times the upper limit of normal, that there is an inverse relationship between BMI and serum iron studies in patients with NAFLD (i.e., subjects with low TS and low SF had significantly higher BMI) (13) . We have also previously shown that subjects with hepatic iron staining had higher levels of serum hepcidin (14) . The goal of this study was to examine the relationship between circulating hepcidin level, obesity-induced systemic inflammation, and iron deficiency and to identify the prevalence of and associated risk factors for iron deficiency in patients with NAFLD.
Subjects and Methods

Subjects
Six hundred and seventy five adult (age>18 yrs) subjects enrolled in NASH CRN studies between October 2004 and February 2008, with biopsy proven NAFLD (defined as >5% steatosis) and serum iron studies within 6 months of the liver biopsy were studied. The NASH CRN Database and PIVENS Trial inclusion/exclusion criteria have been reported elsewhere (15, 16) . Demographic information including age, sex, ethnicity and race and a detailed medical history including co-morbidities such as history of DM, hypertension and hyperlipidemia and menstrual history in women were obtained from patient interviews during screening. Dietary consumption of iron, vitamin C, tea and coffee and supplemental vitamin C were determined from the Block 98 food frequency questionnaire (NutritionQuest, Berkeley, CA); alcohol consumption was determined from the Alcohol Use Disorders Identification Test Consumption (AUDIT-C) questionnaires (17) . A complete physical examination including measurement of weight, height, waist and hip circumference was obtained. Subjects with a BMI of ≥ 30 were defined as obese. ID was defined as transferrin saturation (TS; serum iron/total iron binding capacity) below 20%, indicative of iron deficiency (18, 19) . We also investigated the presence of iron deficiency anemia in our cohort using the criteria of serum ferritin<30, TS<20 and hemoglobin<12 in females and <13 in males; only 15 subjects met this criteria and therefore we did not analyze this subset separately. The prevalence of the metabolic syndrome (MS) in this cohort was defined using the World Health Organization criteria. All subjects gave written informed consent and the study was approved by the institutional review board at each local site of the NASH CRN.
Serologic data
Clinical laboratory data including hematologic, hepatic and metabolic, lipid and serum iron assessments were analyzed for subjects with values collected within 6 months of the liver biopsy. Serum hepcidin levels, available in 558 subjects, were determined by ELISA (Intrinsic LifeSciences, San Diego, CA) (20) . The lower limit of detection in this assay is 5 ng/ml. Eight subject values were below this limit and a value of 5ng was imputed for the analysis. Plasma IL6 and IL1β levels, available in 371 and 242 subjects, respectively, were determined using Luminex technology and the human cytokine LINCOplex kit (Catalog number HCYTO-60K, Millipore, St. Charles, MO). The lower limit of detection for the assays were 0.79 and 0.19 pg/mL, respectively. Two subject IL6 values were below this limit and a value of 0.79 pg/mL was imputed for the analysis. Fifty two IL1β values were below this limit including 13 ID subjects. A value of 0.19 pg/mL was imputed for the analysis.
HFE genotyping
We examined the relationship between ID and the presence of mutations in the hemochromatosis gene HFE, which influence hepcidin production. Genotyping for the two common HFE mutations C282Y (rs1800562) and H63D (rs1799945) was performed using a real time genotyping assay as previously described (14) . HFE genotyping data was available in 500 subjects.
Liver histology
All patients underwent a liver biopsy which was stained for hematoxylin-eosin, Masson's trichrome and Perls' iron stain. Histologic features of NAFLD and iron accumulation were assessed by the pathology committee of the NASH CRN in a centralized consensus review format, as previously described (21) . NAFLD activity score (NAS, range 1-8) was tabulated by summing scores for steatosis, lobular inflammation, and ballooning degeneration.
Statistical analysis
Data were compared using the Wilcoxon Rank Sum test for continuous variables and the Fisher's exact test for categorical variables. Univariate logistic and stepwise forward multivariate logistic regression (p value of <0.20 was used as a cutoff for incorporation into the model) were used to identify independent predictors for iron deficiency. Models were also created to identify risk factors in each sex. Differences in histological features such as fibrosis stage, steatosis and lobular inflammation grade were analyzed using ordinal regression. All analyses were performed using STATA (version 12, College Station, TX, USA). Nominal, two-sided p-values were used and were considered to be statistically significant if p<0.05. No adjustments for multiple comparisons were made.
Results
Patient characteristics
Six hundred seventy five subjects (mean age of 48 ± 12 years) with biopsy-proven NAFLD (defined as >5% steatosis) and serum iron assessments within six months of their liver biopsy were evaluated in the present study. 34% (231 subjects) were ID and 66% (444 subjects) were iron normal (TS≥20%). Overall the majority of subjects in this study cohort were white (84%), obese (70%) and female (63%). Patient characteristics including clinical, demographic, racial, and specific dietary/behavioral factors thought to effect iron absorption, such as dietary iron, vitamin C, caffeine and alcohol consumption are summarized in Table  1 . Subjects with ID were significantly more likely to be female, obese, and with greater waist circumference and BMI compared to iron normal subjects. ID subjects were also more likely to have DM and MS. When we analyzed the presence of iron deficiency according to race, we found that the prevalence of ID was significantly increased among those with either Black or AI/AN race. Lower alcohol consumption was the only dietary factor that was associated with ID. There were no differences in the presence of the C282Y or H63D HFE hemochromatosis gene mutations between ID and iron normal groups.
The proportion of subjects that were ID compared to iron normal, analyzed according to sex and obesity status is shown in Figure 1 . Women were much more likely to be ID compared to men (43% vs 20%, p<0.001). Additionally, a greater proportion of women with ID were obese compared to men (35% vs 14%, p<0.001). A higher percentage of women with regular periods were ID compared to postmenopausal women, although this difference was not statistically significant (51% vs. 40%, respectively, p=0.15). Obesity was more prevalent among ID women with regular periods compared to ID women without periods (46% vs 29%, p=0.042).
Differences in laboratory tests between iron deficient and iron normal subjects
Significant differences in routine clinical laboratory assessments, serum iron studies and pro-inflammatory cytokines IL6 and IL1β between the two groups of patients are shown in Table 2 . ID subjects had lower ALT, and total and direct bilirubin levels, but higher ceruloplasmin and HbA1c levels, AST/ALT ratios, and platelet counts. ID subjects had significantly lower hemoglobin, serum iron, ferritin and TS and higher total iron binding capacity, consistent with an iron depleted state. Plasma levels of IL6 and IL1β were significantly increased in ID subjects compared to iron normal subjects (p≤0.0001; p≤0.008, Table 2 ), suggesting systemic inflammation may be greater in ID compared to iron normal subjects. Figure 2A shows the relative mean serum hepcidin level in ID subjects compared to iron normal subjects stratified according to sex, menstrual status, or the presence of obesity, diabetes and metabolic syndrome. Serum hepcidin levels were lower in ID subjects compared to iron normal subjects (p<0.05), except in males. Women who reported having regular periods showed the largest difference in serum hepcidin (−39%; 41 vs 67 ng/ml, p=0.03) between ID and iron normal subjects, respectively, and the lowest mean levels among all groups, reflecting the effect of blood loss on circulating hepcidin levels.
Relationship of circulating hepcidin levels and factors associated with ID
We compared serum hepcidin levels in obese vs non obese ID patients, stratified according to sex and menstrual status ( Figure 2B ). In each group, non-obese ID subjects had 13-14% lower serum hepcidin levels compared to obese ID subjects. We also observed that obese ID women with regular periods had significantly lower serum hepcidin levels compared to obese ID women with no periods (42 vs 64 ng/ml, respectively, p=0.006), suggesting iron loss effectively reduces serum hepcidin even in the setting of obesity.
Histologic differences between groups
No significant difference in mean grade of steatosis (range 0-3; 1.7±0.9 vs 1.8±0.9), lobular inflammation (range 0-3; 1.6±0.7 vs 1.6±0.7), portal inflammation (range 0-2; 1.1±0.6 vs 1.0±0.6), ballooning (range 0-2; 1.1±0.9 vs 1.1±0.9) fibrosis (range 0-4; 1.5±1.3 vs 1.6±1.3) or NAS index (range 0-8; 4.4±1.7 vs 4.5±1.6) was noted between the ID and iron normal subjects, respectively.
Factors associated with the presence of iron deficiency
Logistic regression analysis was performed to investigate potential risk factors for ID in this population (see Table 3 ). ID was associated with female sex, obesity, increased BMI and waist circumference, presence of DM or MS, fewer alcoholic drinks consumed per week and Black and AI/AN race in univariate analysis. To investigate the relationship between the combined effects of these factors on ID, stepwise multivariate logistic regression modeling was performed with ID as the dependent variable and each of the variables significantly associated with ID on univariate analysis as independent variables; a p value of <0.20 was used as a cutoff for incorporation into the model. Overall, female sex, increased BMI, Black and AI/AN race and decreased ALT and serum hepcidin were independently associated with ID. In addition, multivariate regression analysis was performed in men and women as two separate groups. BMI, ALT, serum hepcidin and AI/AN race were independently associated with ID in women, while in men only waist circumference was independently associated with ID. Potential factors which could explain the ID phenotype in the Black and AI/AN race are shown in Table 4 . The only significant difference between Black subjects was that none of the ID Black subjects took supplemental vitamin C, which increases intestinal iron absorption (p=0.02). AI/AN ID subjects had increased BMI and waist circumference and were more likely to be obese compared to the AI/AN iron normal subjects (p<0.05).
Discussion
Iron deficiency is common in obese children and adults; the cause of this association is not entirely clear and has been linked to a number of factors (2-7). In the present study we found that one third of adult NAFLD subjects were iron deficient as defined by TS<20%, and that female sex, obesity (BMI ≥30), type 2 diabetes and the metabolic syndrome were more common in this cohort. We also found that alcohol consumption is protective against ID, consistent with our previous data from a population-based study (22) . Alcohol has been shown to decrease hepcidin expression, which could lead to increased iron absorption and recycling (23) . Both in vitro and human studies have described that alcohol suppressed hepcidin transcription in the liver and may protect from iron deficiency (24) . However, alcohol intake was unlikely to be a major factor on hepcidin levels in this study, given that excessive alcohol consumption was an exclusion criterion for all NASH CRN studies (15, 16) . There were no differences in the presence of C282Y or H63D HFE hemochromatosis gene mutations between ID and iron normal groups, which is in agreement with our previous report in a related cohort showing that heterozygous C282Y or H63D subjects did not have statistically different levels of serum iron parameters compared to wild type subjects (14) . No other dietary factor was associated with ID, including amount of dietary iron or supplemental and dietary vitamin C or caffeine consumption. In addition, we found that ID was associated with Black or AI/AN race. When each sex was considered separately, in women only BMI and AI/AN race, and only waist circumference in men, were independent predictors of ID on multivariate logistic regression. Obesity was more prevalent among the ID women with regular menses compared to ID women with amenorrhea; this was an interesting observation with no ready explanation and we speculate that amenorrhea maybe secondary to polycystic ovarian syndrome (PCOS) may be contributing as PCOS is associated with increased insulin resistance.
We found that overall, serum hepcidin was lower in ID subjects compared to iron normal subjects, despite increased cytokine levels suggesting the presence of chronic inflammation which would have been expected to increase serum hepcidin. These findings are in agreement with our previous report that subjects with hepatic iron staining had higher levels of serum hepcidin than subjects without stainable hepatic iron (14) . Although it is possible that obesity-induced inflammation-mediated hepcidin up regulation would contribute to the onset of ID among obese people, the decreased circulating hepcidin we observed in our ID subjects in comparison to the iron normal subjects reflects an appropriate physiologic response to current body iron stores; when the body iron stores are low, hepcidin production is decreased resulting in increased intestinal iron absorption and macrophage iron release.
These data suggest that body iron stores rather than chronic inflammation are the primary signal mediating hepcidin levels in our ID NAFLD subjects.
Our data are in agreement with several animal studies suggesting that both iron deficiency, induced by either phlebotomy treatment (25, 26) , or dietary insufficiency (26, 27) , cause down regulation of hepcidin even in the presence of experimentally induced inflammation. In an elegant study by Theurl et al, these authors investigated hepcidin signaling in rat models of anemia of chronic disease (high hepcidin) and anemia of chronic disease with true iron deficiency (anemia of chronic disease/ID; low hepcidin levels) induced by either phlebotomy treatment or dietary iron insufficiency (26) . Despite similarly high levels of STAT3, the inflammatory pathway hepcidin transactivator, in both models, the anemia of chronic disease/ID rats had decreased hepcidin transcription. This effect was mediated by inhibition of bone morphogenic protein-6 expression and reduced phosphorylation and trafficking of SMAD1/5/8. Taken together, these and other data and our results indicate that hepcidin regulation in the presence of multiple divergent signals in vivo maybe determined by the most urgent physiologic needs/strength of the signal within the organism rather than a set hierarchy of hepcidin regulatory signals (7, 26, 28) .
Body iron stores and increased serum ferritin levels have been associated with more severe NAFLD (13, 21) . In this study we did not observe any significant difference in histologic features of NASH between ID and iron normal NAFLD patients. However, subjects with ID had significantly lower ALT levels even after adjusting for age, sex, BMI, DM and NAS (data not shown).
An interesting observation in the current study was that ID was more prevalent among subjects self-described as Black or AI/AN race. When we further investigated the presence of additional risk factors for ID in these subjects we found that AI/AN ID subjects had increased BMI and waist circumference and were more likely to be obese compared to the AI/AN iron normal subjects. We also found that none of the Black ID subjects took supplemental vitamin C, compared to mean consumption of 140 ± 269 mg/day in Black iron normal subjects. However, we interpret these findings with caution given the small number of subjects with these racial backgrounds.
Both obesity and NAFLD are inflammatory conditions and we cannot distinguish the source of inflammation and whether there was an independent effect of obesity on hepcidin level, since all patients in the NASH CRN Database, by definition had NAFLD. Studies have shown that NAFLD patients have significantly more colorectal (CR) neoplasia and early CR cancer compared to those without NAFLD (29) . We did not have data available on screening for colorectal neoplasia; thus, the potential of underlying gastrointestinal bleed from undetected CR neoplasia may potentially be a cause for ID.
In conclusion, our study shows that iron deficiency is common in NAFLD patients. Circulating serum hepcidin levels in NAFLD patients with iron deficiency are low reflecting an appropriate physiologic response of hepcidin signaling to iron deficiency. Obesity and female sex are likely the most important risk factors of ID in NAFLD subjects; however alcohol consumption, presence of diabetes and potentially racial background may also be contributing factors. We conclude that increased hepcidin as a result of obesity-induced systemic inflammation may initially contribute to iron deficiency but once ID is established hepcidin is appropriately down regulated.
Several clinical centers use support from the National Center for Advancing Translational Sciences (NCATS) in conduct of NASH CRN Studies (grants UL1TR000439, UL1TR000077, UL1TR000436, UL1TR000150, UL1TR000424, UL1TR000006, UL1TR000448, UL1TR000040, UL1TR000100, UL1TR000004, UL1TR000423, UL1TR000058, UL1TR000067, UL1TR000454).
This work was supported in part by the Intramural Research Program of the National Cancer Institute.
The authors would like to acknowledge the support of the BRI Genotyping Core facility. We would also like to thank Laura Wilson and Patricia Belt for assistance in preparation of the data. We thank Dr. Mark Westerman at Intrinsic Life Sciences for helpful discussions. 
